Eli Lilly and Co (1LLY.MI)

Compare

770.80

+7.10

+(0.93%)

At close: January 28 at 5:35:14 PM GMT+1

Drugmakers Show Restraint on Price Increases in New Trump Era

Drugmakers raised the list prices of more than 800 prescription drugs for blood pressure, cancer and other conditions by a median 4% at the start of this year. The modest size of the annual increases could help companies avoid criticism of gouging from President Trump while seeking his administration’s support for such priorities as taking aim at the rebates given to middlemen and altering a federal program providing discounts to certain hospitals. Last year’s median price increase was 4.5%.

The Wall Street Journal 4 hours ago

PFE

AMGN

UTHR
Is There An Opportunity With Eli Lilly and Company's (NYSE:LLY) 43% Undervaluation?

Key Insights The projected fair value for Eli Lilly is US$1,419 based on 2 Stage Free Cash Flow to Equity Eli Lilly's...

Simply Wall St. 12 hours ago

LLY
Hims & Hers to Advertise Weight-Loss Shots at the Super Bowl

Telehealth provider will make its big game debut as the semaglutide shortage continues to sustain the firm’s lower-priced injectables.

The Wall Street Journal 13 hours ago

HIMS

LLY
Winners and losers in Monday's DeepSeek shake-up

The introduction of DeepSeek, a Chinese artificial intelligence (AI) startup, triggered a broad market sell-off on Monday, particularly impacting US technology stocks. Yahoo Finance Markets and Data Editor Jared Blikre examines the day's significant market movements amid heightened volatility. While the AI-related concerns notably affected Nvidia's (NVDA) stock price, some major companies bucked the downward trend. Notable gainers during the session included Apple (AAPL), Eli Lilly (LLY), and Walmart (WMT), demonstrating market resilience in certain sectors despite the tech-focused decline. To watch more expert insights and analysis on the latest market action, check out more Asking for a Trend here. This post was written by Angel Smith

Yahoo Finance Video yesterday

^IXIC

^DJI

^GSPC
Trending tickers: Nvidia, Alphabet, Alibaba, Novo Nordisk and GSK

The latest investor updates on stocks that are trending on Monday

Yahoo Finance UK yesterday

^FTSE

BABA

BABAF
Novo Nordisk Surges As Next-Gen Obesity Drug Outperforms

Novo Nordisk stock surged Friday after the obesity kingpin reported strong results for its next-generation weight-loss drug, amycretin.

Investor's Business Daily 4 days ago

NONOF

NVO

LLY
Allurion Catapults 132% On Its Plans To Outdo Eli Lilly, Novo Nordisk

Allurion catapulted Friday after the company said it plans to test its weight-loss technology with an obesity drug.

Investor's Business Daily 4 days ago

NONOF

NVO

ALUR
Novo Nordisk stock pops on phase I data for new weight-loss drug amycretin

Novo Nordisk announces new early clinical trial data for its latest weight loss drug, amecrytin.

Yahoo Finance 4 days ago

NONOF

NVO

LLY
Is Now The Time To Put Eli Lilly (NYSE:LLY) On Your Watchlist?

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

Simply Wall St. 4 days ago

LLY
Lilly confirms date and conference call for fourth-quarter 2024 financial results and 2025 financial guidance announcement

Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2024 financial results and 2025 financial guidance on Feb. 6, 2025. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance and guidance.

PR Newswire 5 days ago

LLY
Eli Lilly (NYSE:LLY) Is Increasing Its Dividend To $1.50

Eli Lilly and Company ( NYSE:LLY ) will increase its dividend from last year's comparable payment on the 10th of March...

Simply Wall St. 10 days ago

LLY
The Score: Goldman Sachs, Nvidia, UnitedHealth and More Stocks That Defined the Week

MARKETS MAIN The Score is a weekly review of the biggest stock moves and the news that drove them. Goldman Sachs A rebound on Wall Street fueled surging profits at banking giants last quarter. On Wednesday, Goldman Sachs JPMorgan Wells Fargo and Citigroup all posted profits that were better than expected.

The Wall Street Journal 11 days ago

M

GS

WFC
Medicare to negotiate prices on 15 drugs, including Ozempic

Medicare seeks to negotiate prices on 15 drugs, including Novo Nordisk's (NVO) GLP-1 weight-loss drugs Ozempic and Wegovy, in new talks. Yahoo Finance senior health reporter Anjalee Khemlani explains the process and the range of other drugs on this new list from pharmaceutical giants Pfizer (PFE), AstraZeneca (AZN), Merck (MRK) To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Luke Carberry Mogan.

Yahoo Finance Video 11 days ago

PFE

MRK

AZN
Here's How Donald Trump Could Shake Up Health Care — And Biotech Stocks

Biotech stocks have slumped 15% since Donald Trump won his second presidency. That's because Trump comes with a lot of unknowns.

Investor's Business Daily 11 days ago

NONOF

NVO

MRNA
Ozempic Among the Next Drugs Up for Medicare Price Negotiations

The list of drugs account for $41 billion in annual Medicare spending, the Biden administration said.

The Wall Street Journal 11 days ago

LLY

PFE

BMY
Eli Lilly Receives FDA Approval for Crohn’s Disease Treatment

Eli Lilly said it received Food and Drug Administration approval for its treatment for moderate to severely-active Crohn’s disease, an inflammatory bowel disease that causes chronic abdominal pain.

The Wall Street Journal 13 days ago

LLY
After Eli Lilly's 7% Slump On Its Guidance Cut, What's Left To Like? A Lot, Says One Analyst.

There's still a lot to like about Eli Lilly stock, an analyst said Wednesday after the weight-loss drugs kingpin cut its sales view.

Investor's Business Daily 13 days ago

LLY

NONOF

NVO
FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease

Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh® (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn's disease in adults. Omvoh is now approved in the U.S. for two types of inflammatory bowel disease (IBD), following its October 2023 approval as a first-in-class treatment for moderately to severely active ulcerative colitis (UC) in adults.1

PR Newswire 13 days ago

LLY
Option Trade Could Return More Than $1,300 On A Wobbly Eli Lilly

Eli Lilly has been struggling since mid-August and is down 20% in the last three months. If Eli Lilly continues to move lower, a bear put spread would be the best way to trade it. A bear put spread is a debit spread.

Investor's Business Daily 13 days ago

LLY
Trending tickers: Meta, Tesla, Eli Lilly, Currys and Vistry

The latest investor updates on stocks that are trending on Wednesday.

Yahoo Finance UK 13 days ago

BVHMF

BVHMY

CURYY

Performance Overview

Return	1LLY.MI	S&P 500
YTD	+3.06%	+2.72%
1-Year	+32.92%	+24.06%
3-Year	+40.91%	+40.24%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Eli Lilly and Co (1LLY.MI)

Drugmakers Show Restraint on Price Increases in New Trump Era

Is There An Opportunity With Eli Lilly and Company's (NYSE:LLY) 43% Undervaluation?

Hims & Hers to Advertise Weight-Loss Shots at the Super Bowl

Winners and losers in Monday's DeepSeek shake-up

Trending tickers: Nvidia, Alphabet, Alibaba, Novo Nordisk and GSK

Novo Nordisk Surges As Next-Gen Obesity Drug Outperforms

Allurion Catapults 132% On Its Plans To Outdo Eli Lilly, Novo Nordisk

Novo Nordisk stock pops on phase I data for new weight-loss drug amycretin

Is Now The Time To Put Eli Lilly (NYSE:LLY) On Your Watchlist?

Lilly confirms date and conference call for fourth-quarter 2024 financial results and 2025 financial guidance announcement

Eli Lilly (NYSE:LLY) Is Increasing Its Dividend To $1.50

The Score: Goldman Sachs, Nvidia, UnitedHealth and More Stocks That Defined the Week

Medicare to negotiate prices on 15 drugs, including Ozempic

Here's How Donald Trump Could Shake Up Health Care — And Biotech Stocks

Ozempic Among the Next Drugs Up for Medicare Price Negotiations

Eli Lilly Receives FDA Approval for Crohn’s Disease Treatment

After Eli Lilly's 7% Slump On Its Guidance Cut, What's Left To Like? A Lot, Says One Analyst.

FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease

Option Trade Could Return More Than $1,300 On A Wobbly Eli Lilly

Trending tickers: Meta, Tesla, Eli Lilly, Currys and Vistry

Performance Overview